

# Application of Singlet Oxygen-Activatable Nanocarriers to Boost X-ray-Induced Photodynamic Therapy and Cascaded Ferroptosis for Breast Cancer

Beibei Zhang<sup>a, b, c, \*</sup>, Hao Liu<sup>a, b, c</sup>, Yifei Wang<sup>a, b, c</sup>, Yong Zhang<sup>a, b, c, \*</sup>, Jingliang Cheng<sup>a, b, c, \*</sup>

<sup>a</sup> Department of Magnetic Resonance Imaging, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450002, P.R. China

<sup>b</sup> Key Laboratory for functional magnetic resonance imaging and molecular imaging of Henan Province, Zhengzhou 450002, P.R. China

<sup>c</sup> Engineering Research Center of medical imaging intelligent diagnosis and treatment of Henan Province, Zhengzhou 450002, P.R. China

E-mail: zhangb0420@126.com (B. Zhang); zzuzhangyong2013@163.com (Y. Zhang);  
fccchengjl@zzu.edu.cn (J. Cheng)

## **Experimental methods**

### **Materials**

RPMI 1640 medium, fetal bovine serum (FBS) and trypsin were purchased from Gibco BRL (Gaithersburg, MD; USA). Cell counting kit-8 (CCK-8) and 4',6-diamidino-2-phenylindole (DAPI) were purchased from Beyotime Biotechnology Co., Ltd. (Nantong; China). Liperfluo was obtained from Beijing Dojindo Biotechnology Co., Ltd (Beijing, China). Annexin V-FITC/PI was purchased from Invitrogen Corporation (IVGN; USA). All other solvents were of analytical grade.

### **Characterization**

The proton nuclear magnetic resonance ( $^1\text{H}$  NMR) spectra were recorded in  $\text{CD}_3\text{SOCD}_3$  on a 400-MHz spectrometer (Avance III, Bruker, Germany). The mean particle size, polydispersity, and zeta potential were measured by dynamic light scattering (DLS) with a Malvern Zetasizer (Nano-ZS, Malvern Instruments, UK). The morphology of nanoparticles was observed by transmission electron microscopy (TEM, Hitachi HT7700). The UV/Vis absorptions of nanoparticles and drug loading efficiency were detected on a UV/Vis spectrophotometer (UV-3600 Shimadzu, Japan). The fluorescence of SOSG was measured using a Hitachi F7000 fluorescence spectrophotometer. *In vivo* imaging of small animals was captured by Xenogen IVIS Lumina system (AMI-934M, USA). *In vivo* imaging of small animals was captured by Xenogen IVIS Lumina system (AMI-934M, USA).

### **Cellular internalization of nanocarriers *in vitro***

For confocal laser scanning microscope (CLSM) observations, 4T1 cells were


seeded onto 14-mm coverslips at a density of  $2 \times 10^4$  cells per well in 1.0 mL of 1640 medium, and cultured at 37 °C with 5% CO<sub>2</sub> for 12 h. The cells were then incubated with NP<sub>VR</sub> or D-NP<sub>VR</sub> for 2, 4 or 6 h, washed with PBS, fixed with 4% paraformaldehyde, and then stained with phalloidin and 4',6-diamidino-2-phenylindole (DAPI) sequentially according to the manufacturer's protocol. The cellular internalization was then visualized on a Zeiss LSM 810 confocal microscope.

### **Biosafety Evaluation**


Twenty healthy BALB/c mice were randomly divided into four groups and received *i.v.* injection daily for three times with PBS, free VP + RLS3, NP<sub>VR</sub>, or D-NP<sub>VR</sub>, respectively. The orbital plexus blood sampling was collected on day 7 for routine blood count, creatinine, urea nitrogen, alanine aminotransferase, and aspartate aminotransferase detection.

### **Statistical Analysis**


Statistical significance was analyzed using a t-test. One-way analysis of variance (ANOVA) was used for comparisons between more than two groups. Unless specially noted, data are shown as mean  $\pm$  SD ( $p < 0.05$ ).




**Figure S1.** Synthetic route of 1,2-bis(2-hydroxyethylthio)ethylene bridged D-HPE.




**Figure S2.**  $^1\text{H}$  NMR spectrum of D-HPE in  $\text{CDCl}_3$  recorded on an AVANCE III 400 MHz spectrometer at  $25\text{ }^\circ\text{C}$ .




**Figure S3.**  $^1\text{H}$  NMR spectrum of HPE in  $\text{CDCl}_3$  recorded on an AVANCE III 400 MHz spectrometer at  $25\text{ }^\circ\text{C}$ .




**Figure S4.** The diameter (A) and morphology (B) change of NP<sub>VR</sub> and D-NP<sub>VR</sub> with X-ray irradiation. The scale bar is 200 nm.




**Figure S5.** Bis(2-hydroxyethylthio)ethylene linker degradation of D-NP<sub>VR</sub> with or without 4 Gy of X-ray radiation.




**Figure S6.** Fluorescent imaging of lipid peroxides in 4T1 cells. The cells were treated by various formulations including VP&RSL3, NP<sub>VR</sub>, and D-NP<sub>VR</sub>.




**Figure S7.** Relative viabilities after incubation with NP<sub>VR</sub> or D-NP<sub>VR</sub> on 4T1, MCF-7 and NIH-3T3 cells.



**Figure S8.** Following *i.v.* injections, the doxorubicin fluorescence observed by CLSM at 24 h with (+) or without (-) X-ray radiation.



**Figure S9.** Body weight change following multiple *i.v.* injections of PBS, free VP&RSL3, NP<sub>VR</sub> or D-NP<sub>VR</sub>.



**Figure S10.** Complete blood count in BALB/c mice after *i.v.* injections (n = 5).

**Table S1.** Drug loading contents (DLC) and encapsulation efficiencies (EE) of VP and RSL3 for NP<sub>VR</sub> and D-NP<sub>VR</sub>.

	DLC (%)		EE (%)	
	VP	RSL3	VP	RSL3
NP <sub>VR</sub>	3.39	3.22	35.9	34.1
D-NP <sub>VR</sub>	3.53	3.07	34.6	30.1